Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Biolex
Introduction
Biolex Therapeutics is a biotechnology firm in the Research Triangle of North Carolina. The company focuses on formation of difficult to synthesize proteins in Lemna, a duckweed.[1] The duckweeds are a family of small aquatic plants that can be grown in sterile culture. Biolex has developed recombinant DNA technology for efficiently producing pharmaceutical proteins in Lemna.[2] Therapeutic glycosylated proteins, such as monoclonal antibodies, have been produced by the Lemna system at Biolex.[3]
Biolex acquired Epicyte Pharmaceutical Inc. on May 6, 2004, and acquired LemnaGene SA of Lyon, France in 2005.[4] Biolex is a privately held company backed by Quaker BioVentures, The Trelys Funds, and Polaris Venture Partners. The term “plantibody” is trademarked by Biolex.
References
- ↑ Goodman Peter S. In N.C., A Second Industrial Revolution: Biotech Surge Shows Manufacturing Still Key to U.S. Economy [1] Washington Post Monday, September 3, 2007
- ↑ John R. Gasdaska, David Spencer and Lynn Dickey “Advantages of Therapeutic Protein Production in the Aquatic Plant Lemna” BioProcessing Journal, Mar/Apr 2003.
- ↑ Cox KM et al. Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor. Nat Biotechnol. 2006 Dec;24(12):1591-7.
- ↑ Biolex Therapeutics Acquires Lemnagene S.A.